1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Sarcomas - Pipeline Review, H2 2013

Sarcomas - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 127 pages

Sarcomas - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Sarcomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcomas.
- A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sarcomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Sarcomas - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Sarcomas Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Sarcomas 10
Sarcomas Therapeutics under Development by Companies 12
Sarcomas Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Sarcomas Therapeutics - Products under Development by Companies 19
Sarcomas Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Sarcomas Therapeutics Development 21
Shionogi and Co., Ltd. 21
AstraZeneca PLC 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Gamida Cell Ltd. 25
Eisai Co., Ltd. 26
Marshall Edwards, Inc. 27
Oncolytics Biotech Inc. 28
Pharmacyclics, Inc. 29
PCI Biotech AS 30
MabVax Therapeutics, Inc. 31
Morphotek, Inc. 32
Philogen S.p.A. 33
Neotropix, Inc. 34
Axelar AB 35
Polaris Group 36
Sarcomas - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
eribulin mesylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
eribulin mesylate - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
cixutumumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
MK-1775 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Fibromun - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
(amphinex + bleomycin sulfate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
NTX-010 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
AXL-1717 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
pracinostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
pelareorep - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
MORAb-004 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
X-396 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
X-379 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
Angiotensin 1-7 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Mixed Bacterial Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
ADI-PEG20 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Personalized Peptide Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Sarcoma Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Autologous Tumor Cell Vaccine + [celecoxib] - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
1-B7 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
EC-8042 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
doxorubicin liposomal - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
MN-4 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
Peptide Cocktail Vaccine - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
nitroxoline - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
GW-441756 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
Sarcomas Therapeutics - Drug Profile Updates 91
Sarcomas Therapeutics - Discontinued Products 115
Sarcomas Therapeutics - Dormant Products 116
Sarcomas - Product Development Milestones 117
Featured News and Press Releases 117
Jun 27, 2013: EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma 117
May 31, 2013: Virttu Biologics Announces Extension Of US Phase I Study Of Seprehvir To Include Systemic Delivery Of Oncolytic Virus 118
Apr 08, 2013: Two-Drug Combination More Effective In Treating Sarcomas, Moffitt Cancer Center Study Shows 118
Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types 119
Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says 120
Jun 12, 2012: Polaris's ADI-PEG 20 Demonstrates Potential Anticancer Activity In Various Metastatic Sarcomas And Bladder Cancers 121
May 17, 2012: Curis Announces Presentation Of Erivedge Clinical Data At ASCO Annual Meeting 122
Feb 28, 2012: Polaris Group Doses First Patient In Phase I Clinical Trial Of ADI-PEG 20 In Pediatric Patients 123
Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer 124
Dec 02, 2011: Moffitt Cancer Center Researchers Find MK1775 Active Against Sarcomas 124
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127



List of Tables

Number of Products Under Development for Sarcomas, H2 2013 10
Products under Development for Sarcomas - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Shionogi and Co., Ltd., H2 2013 21
AstraZeneca PLC, H2 2013 22
Eli Lilly and Company, H2 2013 23
GlaxoSmithKline plc, H2 2013 24
Gamida Cell Ltd., H2 2013 25
Eisai Co., Ltd., H2 2013 26
Marshall Edwards, Inc., H2 2013 27
Oncolytics Biotech Inc., H2 2013 28
Pharmacyclics, Inc., H2 2013 29
PCI Biotech AS, H2 2013 30
MabVax Therapeutics, Inc., H2 2013 31
Morphotek, Inc., H2 2013 32
Philogen S.p.A., H2 2013 33
Neotropix, Inc., H2 2013 34
Axelar AB, H2 2013 35
Polaris Group, H2 2013 36
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Stage and Molecule Type, H2 2013 43
Sarcomas Therapeutics - Drug Profile Updates 91
Sarcomas Therapeutics - Discontinued Products 115
Sarcomas Therapeutics - Dormant Products 116



List of Figures

Number of Products under Development for Sarcomas, H2 2013 10
Products under Development for Sarcomas - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Route of Administration, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Molecule Type, H2 2013 41
Assessment by Stage and Molecule Type, H2 2013 42



Companies Mentioned

Shionogi and Co., Ltd.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Gamida Cell Ltd.
Eisai Co., Ltd.
Marshall Edwards, Inc.
Oncolytics Biotech Inc.
Pharmacyclics, Inc.
PCI Biotech AS
MabVax Therapeutics, Inc.
Morphotek, Inc.
Philogen S.p.A.
Neotropix, Inc.
Axelar AB
Polaris Group

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.